Daré Bioscience reports FY2023 net loss $30.1M, cash $10.5M; XACIATO launched, Ovaprene Phase 3 recruiting

Dare Bioscience, Inc.

Net loss of $30.1M for FY2023; revenue of $2.8M from XACIATO milestone payments.
Cash and equivalents $10.5M at Dec 31, 2023; received $4.7M in grant funding and $17M in offerings/financing.
XACIATO launched in U.S. via Organon; Daré eligible for double-digit royalties and up to $180M milestones.
Ovaprene Phase 3 pivotal study recruiting at 17 U.S. sites; non-hormonal monthly contraceptive candidate.
Sildenafil Cream completed Phase 2b; FDA feedback on Phase 3 design expected in Q2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dare Bioscience, Inc. reported financial results for the fiscal year ended December 31, 2023.

Period: the fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 28, 2024, Daré Bioscience, Inc. (the “Company”), issued a press release announcing its financial results for the fiscal year ended December 31, 2023

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Dare Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-011615

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.